From an investigational oral peptide for psoriasis and a new oral Janus kinase (JAK) inhibitor for hidradenitis suppurativa (HS), the dermatology pipeline is full. Maui Derm Founder George Martin, MD, provides a glimpse into what’s coming and also highlights some of the latest drug approvals in the field, including a Bruton’s tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria and advanced topicals for seborrheic dermatitis, atopic dermatitis, and psoriasis from his talk at Maui Derm Caribbean 2026 in San Juan, Puerto Rico.